Company Overview
Cognition Therapeutics, Inc., a privately held biopharmaceutical company, is focused on the development of a pipeline of disease-modifying small molecule drug candidates that are designed to normalize the impaired membrane trafficking pathways that are the root cause of many CNS disorders. By so doing, Cognition’s drug candidates aim to protect and restore synaptic function, thereby preserving brain health. The Company's lead candidate, Elayta™, is currently in Phase 2 development for the treatment of mild-to-moderate Alzheimer's disease. Cognition’s three ongoing clinical trials – SPARC, SNAP and SHINE – are supported by grants from the National Institute on Aging.